Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 20, 2016updated 22 Nov 2021 6:11am

AbbVie and University of Chicago collaborate on cancer research

Biopharmaceutical company AbbVie has collaborated with the University of Chicago to advance cancer research over the next five years.

Abbvie

Biopharmaceutical company AbbVie has collaborated with the University of Chicago to advance cancer research over the next five years.

The collaboration agreement is aimed at improving the pace of discovery and advance medical research in oncology at both organisations.

As per the agreed terms, AbbVie will fund preclinical research, clinical trials and possible future programmes at the university resulting from this partnership.

The company will also have an exclusive option to license some of the discoveries at the university.

The partners will jointly work to advance research in several areas of oncology such as breast, lung, prostate, colorectal and hematological cancer.

University of Chicago medical affairs executive vice-president, Kenneth S. Polonsky, said: “University of Chicago researchers and clinicians have worked closely with AbbVie scientists in areas such as immunology and oncology for some time.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

“This agreement adds depth to that established and productive collaboration. The increased level of interaction should speed progress in medical care, beginning with cancer patients.”

Scientists and physicians at the university will have access to new therapies developed by AbbVie, for use in preclinical research funded under the collaboration.

AbbVie researchers will in turn have access to data commons technology developed by the Centre for Data Intensive Science at the university and the core technical team that is developing the technology.

“University of Chicago researchers and clinicians have worked closely with AbbVie scientists in areas such as immunology and oncology for some time.”

Researchers from the university and AbbVie will also take part in an annual symposium, where scientists from both institutions come together to discuss research and evaluate potential new projects.

Meanwhile, the company is to enter into a partnership with clinical-stage biopharmaceutical company argenx to develop and commercialise ARGX-115.

ARGX-115 is argenx’s preclinical-stage human antibody programme targeting the novel immuno-oncology target GARP, a protein that is believed to contribute to immuno-suppressive effects of T-cells.

AbbVie will pay $40m in upfront payment to argenx for the exclusive option to license ARGX-115 and near-term preclinical milestones of $20m.


Image: Researchers work in a laboratory at the University of Chicago. Photo: courtesy of Jean Lachat.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU